Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Docetaxel,DCTXL001,2021,USA,MDV,350,68,35,65,27.5,42,85,15,15,30,40,15,45,30,15,10,20,35,30,18,7,4,9,6,25,60,45,FAC,AC,TC,CMF,12,8,10,30,70,55,20,45,35,60,2
Docetaxel,DCTXL002,2022,Canada,Claim Database,420,72,40,60,28.1,38,80,18,12,28,42,18,40,32,18,10,18,32,35,20,8,5,10,7,22,58,42,FEC,EC,Docetaxel/Cyclophosphamide,AC-T,10,9,11,32,72,58,18,42,40,62,2.5
Docetaxel,DCTXL003,2023,UK,MDV,280,65,38,62,26.9,45,82,20,14,29,41,16,43,31,16,10,19,34,32,19,7,4,9,6,24,59,44,Taxotere/FEC,EC,Docetaxel/Carboplatin,CMF,11,8,10,31,71,56,19,43,38,61,2.2
Docetaxel,DCTXL004,2024,Germany,Claim Database,480,70,42,58,27.8,40,78,17,13,27,43,17,39,33,17,11,17,31,36,21,9,6,11,8,23,57,41,Docetaxel/AC,FEC,Docetaxel/Doxorubicin/Cyclophosphamide,AC-TH,9,10,12,33,73,59,17,41,42,63,2.7
Docetaxel,DCTXL005,2023,France,MDV,300,67,36,64,27.2,43,84,19,16,31,39,14,44,30,15,11,21,33,31,17,6,3,8,5,26,61,46,FEC-T,AC,Docetaxel/Cyclophosphamide,CMF,13,7,9,29,69,54,21,44,35,59,2.1
